Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients

British Journal of Cancer

Volumn 103, Issue 5, 2010, Pages 642-648

  Russo, M ^a   Spagnuolo, C ^a   Volpe, S ^b   Mupo, A ^a   Tedesco, I ^a   Russo, G L ^a  

^a CNR   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

Author keywords

apoptosis; CD95; chronic lymphocytic leukaemia; fludarabine; quercetin; TRAIL

Indexed keywords

CASPASE 3; CASPASE 9; DEATH RECEPTOR; FAS ANTIBODY; FLUDARABINE; LIPOCORTIN 5; QUERCETIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL;

ADULT; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CELLS, CULTURED; DRUG SYNERGISM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; QUERCETIN; RECEPTORS, DEATH DOMAIN; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VIDARABINE;

EID: 77955982848     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605794     Document Type: Article

References (40)

1. Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71(10): 1397-1421
2. Binet JL (1993) Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL. Nouv Rev Fr Hematol 35(1): 5-7
3. Bischoff SC (2008) Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 11(6): 733-740
4. Bomstein Y, Yuklea M, Radnay J, Shapiro H, Afanasyev F, Yarkoni S, Lishner M (2003) The antiapoptotic effects of blood constituents in patients with chronic lymphocytic leukemia. Eur J Haematol 70(5): 290-295
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
6. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6): 1840-1847
7. Day AJ, Gee JM, DuPont MS, Johnson IT, Williamson G (2003) Absorption of quercetin-3-glucoside and quercetin-4-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. Biochem Pharmacol 65(7): 1199-1206
8. Debatin KM, Krammer PH (2004) Death receptors in chemotherapy and cancer. Oncogene 23(16): 2950-2966
9. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Dohner H, Brittinger G, Emmerich B, Hallek M (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3): 885-891
10. Fautz R, Husein B, Hechenberger C (1991) Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutat Res 253: 173-179
11. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2(4): 659-668
12. Fimognari C, Lenzi M, Hrelia P (2008) Chemoprevention of cancer by isothiocyanates and anthocyanins: mechanisms of action and structure-activity relationship. Curr Med Chem 15(5): 440-447
13. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12): 5446-5456
14. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45(11): 2179-2205
15. Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2(4): 277-288
16. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and pre-dnisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347(9013): 1432-1438
17. Kaufmann SH, Steensma DP (2005) On the TRAIL of a new therapy for leukemia. Leukemia 19(12): 2195-2202
18. Kim JY, Kim EH, Park SS, Lim JH, Kwon TK, Choi KS (2008a) Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. J Cell Biochem 105(6): 1386-1398
19. Kim YH, Lee DH, Jeong JH, Guo ZS, Lee YJ (2008b) Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol 75(10): 1946-1958
20. Kuida K (2000) Caspase-9. Int J Biochem Cell Biol 32(2): 121-124
21. Lamson DW, Brignall MS (2000) Antioxidants and cancer, part 3: quercetin. Altern Med Rev 5(3): 196-208
22. Lugli E, Ferraresi R, Roat E, Troiano L, Pinti M, Nasi M, Nemes E, Bertoncelli L, Gibellini L, Salomoni P, Cooper EL, Cossarizza A (2009) Quercetin inhibits lymphocyte activation and proliferation without inducing apoptosis in peripheral mononuclear cells. Leuk Res 33(1): 140-150
23. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21(44): 6809-6818
24. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12(7): 773-782
25. Mansour A, Chang VT, Srinivas S, Harrison J, Raveche E (2007) Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein. Cancer Immunol Immunother 56(4): 501-514
26. Murakami A, Ashida H, Terao J (2008) Multitargeted cancer prevention by quercetin. Cancer Lett 269(2): 315-325
27. Okamoto T (2005) Safety of quercetin for clinical application (Review). Int J Mol Med 16(2): 275-278
28. Packham G, Stevenson FK (2005) Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 114(4): 441-449
29. Papenfuss K, Cordier SM, Walczak H (2008) Death receptors as targets for anti-cancer therapy. J Cell Mol Med 12(6B): 2566-2585
30. Pleyer L, Egle A, Hartmann TN, Greil R (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 6(7): 405-418
31. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A (2007) Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 6(9): 2591-2599
32. Russo GL (2007) Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 74(4): 533-544
33. Russo M, Mupo A, Spagnuolo C, Russo GL (2010) Exploring death receptor pathways as selective targets in cancer therapy. Biochem Pharmacol 8(5): 674-682
34. Russo M, Nigro P, Rosiello R, D'Arienzo R, Russo GL (2007) Quercetin enhances CD95-and TRAIL-induced apoptosis in leukemia cell lines. Leukemia 21(5): 1130-1133
35. Russo M, Palumbo R, Mupo A, Tosto M, Iacomino G, Scognamiglio A, Tedesco I, Galano G, Russo GL (2003) Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase Calpha. Oncogene 22(21): 3330-3342
36. Russo M, Palumbo R, Tedesco I, Mazzarella G, Russo P, Iacomino G, Russo GL (1999) Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in HPB-ALL cell line. FEBS Lett 462(3): 322-328
37. Schroers R, Griesinger F, Trümper L, Haase D, Kulle B, Klein-Hitpass L, Sellmann L, Dührsen U, Dürig J (2005) Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 19(5): 750-758.
38. Siegelin MD, Reuss DE, Habel A, Rami A, von Deimling A (2009) Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol 11(2): 122-131
39. Stegmeier F, Warmuth M, Sellers WR, Dorsch M (2010) Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther 87(5): 543-552
40. Yee KW, O'Brien SM (2006) Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 81(8): 1105-1129